-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – VT-1021 in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VT-1021 in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. VT-1021 in Triple-Negative Breast Cancer (TNBC) Drug Details: VT-1021 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – VT-1598 in Coccidioidomycosis
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. VT-1598 in Coccidioidomycosis Drug Details: VT-1598 was under development for the treatment of invasive fungal...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Adrabetadex in Atherosclerosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Adrabetadex in Atherosclerosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Adrabetadex in Atherosclerosis Drug Details: Adrabetadex is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Adrabetadex in Coronary Artery Disease (CAD) (Ischemic Heart Disease)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Adrabetadex in Coronary Artery Disease (CAD) (Ischemic Heart Disease) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Adrabetadex in Coronary Artery Disease (CAD) (Ischemic...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Seviteronel in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Seviteronel in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Seviteronel in Triple-Negative Breast Cancer (TNBC) Drug Details: Seviteronel (VT-464)...
-
Company Insights
Innovation and Patenting activity of VT Holdings Co Ltd Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of VT Holdings Co Ltd Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – VT-1021 in Gliosarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VT-1021 in Gliosarcoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. VT-1021 in Gliosarcoma Drug Details: VT-1021 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – VT-1021 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VT-1021 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. VT-1021 in Solid Tumor Drug Details: VT-1021 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – VT-1598 in Cryptococcal Meningitis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VT-1598 in Cryptococcal Meningitis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.VT-1598 in Cryptococcal MeningitisDrug Details:VT-1598 is under development for the treatment of invasive...